Paper40323013
APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.
Garcia NMG and 7 others. Cancer Res Commun, 2025. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer. Papers, record 40323013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40323013
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Resistance, Neoplasm | Major topic |
| Lung Neoplasms | Major topic |
| Cytidine Deaminase | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Minor Histocompatibility Antigens | Major topic |
| Humans | |
| ErbB Receptors | |
| Cell Line, Tumor | |
| Gefitinib | |
| Mutation | |
| Cell Survival | |
| Gene Expression Regulation, Neoplastic | |
| APOBEC Deaminases |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA015704 | NCI NIH HHS | United States | P30CA015704 | PubMed and NIH | NIH RePORTER |
| R01 CA208042 | NCI NIH HHS | United States | R01CA208042 | PubMed and NIH | NIH RePORTER |
| R01 CA285322 | NCI NIH HHS | United States | R01CA285322 | PubMed and NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 37461590 |
Source PubMed
References83
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27730215 | The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. | Sci Adv | 2016 | https://conductscience.org/library/papers/27730215 | PubMed |
| 2 | 22407829 | Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22407829 | PubMed |
| 3 | 25661795 | Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. | J Clin Pathol | 2015 | https://conductscience.org/library/papers/25661795 | PubMed |
| 4 | 18093943 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/18093943 | PubMed |
| 5 | 26537451 | Recombinase-based conditional and reversible gene regulation via XTR alleles. | Nat Commun | 2015 | https://conductscience.org/library/papers/26537451 | PubMed |
| 6 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 7 | 26799287 | Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. | Oncotarget | 2017 | https://conductscience.org/library/papers/26799287 | PubMed |
| 8 | 28787442 | Comparative transcriptomes of adenocarcinomas and squamous cell carcinomas reveal molecular similarities that span classical anatomic boundaries. | PLoS Genet | 2017 | https://conductscience.org/library/papers/28787442 | PubMed |
| 9 | 28284717 | Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma. | Am J Pathol | 2017 | https://conductscience.org/library/papers/28284717 | PubMed |
| 10 | 33947663 | Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33947663 | PubMed |
| 11 | 31228622 | Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. | J Thorac Oncol | 2019 | https://conductscience.org/library/papers/31228622 | PubMed |
| 12 | 26221054 | Maintaining epithelial stemness with p63. | Sci Signal | 2015 | https://conductscience.org/library/papers/26221054 | PubMed |
| 13 | 25555954 | Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment. | Ann Thorac Surg | 2015 | https://conductscience.org/library/papers/25555954 | PubMed |
| 14 | 33750895 | Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer. | Oncogene | 2021 | https://conductscience.org/library/papers/33750895 | PubMed |
| 15 | 31681582 | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies. | Front Oncol | 2019 | https://conductscience.org/library/papers/31681582 | PubMed |
| 16 | 24893891 | AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24893891 | PubMed |
| 17 | 17699786 | Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. | Cancer Res | 2007 | https://conductscience.org/library/papers/17699786 | PubMed |
| 18 | 38049664 | The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. | Nat Genet | 2024 | https://conductscience.org/library/papers/38049664 | PubMed |
| 19 | 28445112 | Tracking the Evolution of Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28445112 | PubMed |
| 20 | 20371346 | A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. | Cell | 2010 | https://conductscience.org/library/papers/20371346 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898467 | Cellular memory after cancer therapy: persistence after drug withdrawal, maintenance across cell divisions, and responses to rechallenge. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42898467 | PubMed |
| 42535079 | Association of APOBEC mutagenesis with stromal and endothelial niche remodeling and PCDH9-linked signaling alterations in colorectal cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42535079 | PubMed |
| 42427788 | Collapsing retroviruses for efficient delivery of viro-toxic cargoes. | bioRxiv | 2026 | https://conductscience.org/library/papers/42427788 | PubMed |
| 41675410 | Differential effects on tumor progression by APOBEC3A, APOBEC3B, and APOBEC3H Haplotype I in a breast cancer mouse xenograft model. | Front Genet | 2025 | https://conductscience.org/library/papers/41675410 | PubMed |
| 41501001 | APOBEC3C coordinates DDX5 in R-loop resolution and dynamic control of Chk1-mediated stress-responsive circuitry as a prerequisite for gemcitabine resistance in p53-deficient cells. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41501001 | PubMed |
| 41162355 | BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability. | Nat Commun | 2025 | https://conductscience.org/library/papers/41162355 | PubMed |
| 40781226 | Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40781226 | PubMed |
| 39138145 | Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39138145 | PubMed |
| 39047499 | Regulation, functional impact, and therapeutic targeting of APOBEC3A in cancer. | DNA Repair (Amst) | 2024 | https://conductscience.org/library/papers/39047499 | PubMed |
| 38473364 | Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies the Emergence of Drug-Tolerant Cancer Cells. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473364 | PubMed |
| 38254863 | APOBEC Mutagenesis in Cancer Development and Susceptibility. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38254863 | PubMed |
| 38049664 | The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. | Nat Genet | 2024 | https://conductscience.org/library/papers/38049664 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| APOBEC3B | 9582 | PubTator's text mining | https://conductscience.org/library/genes/9582 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| TP63 | 8626 | PubTator's text mining | https://conductscience.org/library/genes/8626 | NCBI Gene |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| BioProject | PRJNA1235703 |
Source BioProject
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40323013
GET https://conductscience.org/api/papers/v1/40323013/references?page=2